Akèy › Kansè pwostat rezistan a kastasyon › Kalifòni
Etid klinik pou Kansè pwostat rezistan a kastasyon nan Kalifòni
11 etid pou Kansè pwostat rezistan a kastasyon ap chèche patisipan nan sit nan Kalifòni.
Vil nan Kalifòni
Tèks ofisyèl etid la (Anglè)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- MemorialCare Orange Coast Medical Center, Fountain Valley
- University Of California San Diego, La Jolla
- Cancer and Blood Specialty Clinic, Los Alamitos
- ak 6 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- University of California at San Diego, La Jolla
- Cedars Sinai Medical Center, Los Angeles
- Ronald Reagan UCLA Medical Center, Los Angeles
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 25, 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- START Los Angeles, Los Angeles
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 24, 2026 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- UCLA Hematology & Oncology ( Site 0003), Los Angeles
- University of California-Irvine Medical Center ( Site 0016), Orange
- UCSF Medical Center at Mission Bay ( Site 0034), San Francisco
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- UCSD Moores Cancer Center ( Site 0039), La Jolla
- UCLA Hematology/Oncology - Santa Monica ( Site 0044), Los Angeles
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- UCI Health Chao Family Comprehensive Cancer Center, Orange
- Investigational Site Number: 403, Palo Alto
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 10, 2026 · NCT05997615Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
- ak 2 plis
Ap rekriteFaz 1
Laj 18 a 100 · Gason · Mizajou Aug 13, 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Stanford Cancer Center, Palo Alto
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Aug 10, 2026 · NCT0606784164Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- Stanford Cancer Institute, Stanford
Ap rekriteFaz 1/2
Laj 18 ak plis · Gason · Mizajou May 6, 2026 · NCT0486860418F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- VA Greater Los Angeles Healthcare System, Los Angeles
Ap rekriteFaz 4
Laj 18 ak plis · Gason · Mizajou Nov 27, 2024 · NCT06706921Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.